BACKGROUND Randomized controlled trials have demonstrated the safety and efficacy of drug-coated balloons for
Micari et al. Patient follow-up is displayed through 24 months. A total of 1,406 intent-to-treat patients were included in this analysis.
Global Study included 1,416 subjects, of whom 1,406
were treated with the paclitaxel DCB and included in the intent-to-treat group. Clinical follow-up is shown in Figure 1 . The rate of compliance for follow-up within the pre-specified window was 77.6% (n ¼ 930 of 1, 199) . Baseline demographics and characteristics are reported in Tables 1 and 2 .
Provisional stents were implanted in 353 patients (25.3%) and 373 lesions (21.2%) ( Table 2 ). Of these, 24.4% (n ¼ 91 of 373) were spot stented, 37.8%
(n ¼ 141 of 373) were partial lesion coverage, and 37.8% (n ¼ 141 of 373) were whole lesion coverage. Table 3 ).
Lesions $15 cm and lesions with popliteal involvement had significantly higher rates of CD TLR through 24 months (p < 0.001). The mean lesion length was 13.4 AE 9.1 cm for subjects with SFA-alone lesions and 17.4 AE 10.6 cm for subjects with lesions that had popliteal artery involvement (p < 0.001). Values are mean AE SD (N) or % (n/N). *Summaries are based on nonmissing assessments. In some cases, baseline demographic or clinical data were not available, and therefore the total number of subjects for that variable is <1,406. †Defined as baseline creatinine $1.5 mg/dl. ‡Because of protocol violations, one Rutherford class 1 subject and 36 Rutherford class 5 subjects were enrolled and included in the analysis. §For subjects with bilateral disease, ABI is included for each target limb.
ABI ¼ ankle-brachial index. Values are % (n/N) or mean AE SD (N). *Summaries are based on nonmissing assessments. In some cases, baseline or clinical data were not available, and therefore the total number of lesions for that variable is <1,773. †Severe calcification defined as calcification with circumference $180 (both sides of vessel at the same location) and length greater than or equal to one-half of the total lesion length. ‡Device success defined as successful delivery, inflation, deflation, and retrieval of the intact study balloon device without burst below the rated burst pressure. This analysis is device (balloon) based. §Procedural success defined as residual stenosis of #50% for nonstented subjects or #30% for stented subjects by core laboratory assessment (site-reported estimate was used if core laboratory assessment was not available). This analysis is lesion based. ¶Clinical success defined as procedural success without procedural complications (death, major target limb amputation, thrombosis of the target lesion, or target vessel revascularization) before discharge. This analysis is subject based.
Micari et al. Number at risk represents the number at the beginning of the 60-day window before each follow-up interval.
lesions were total occlusions, and 10.2% were severely calcified. Importantly, calcium definitions between these trials were different. Target lesion not occluded Target Micari et al. Values are n (%) or mean AE SD (n). *An independent clinical events committee adjudicated all major adverse events. †Event rates expressed as a proportion: the number of subjects with events is the numerator, and the number of subjects with at least 660 days of clinical follow-up is the denominator. ‡CD TLR defined as any reintervention within the target lesion(s) due to symptoms or drop of ABI of $20% or >0.15 compared with post-index procedure baseline ABI. §The primary safety composite endpoint was freedom from device-and procedure-related mortality through 30 days, and freedom from major target limb amputation and CD TVR within 12 months post-index procedure. ¶Major adverse event defined as all-cause mortality, CD TVR, major target limb amputation, thrombosis at the target lesion site.
TVR ¼ target vessel revascularization; other abbreviations as in Tables 1 and 3 . Values are % (n/N). Micari et al.
